There is a project management joke that the first 90% of a project takes 90% of the time, whereas the last 10% of the project takes the other 90% of the time.

There is a project management joke that the first 90% of a project takes 90% of the time, whereas the last 10% of the project takes the other 90% of the time.

Scientists at the University of Connecticut have made progress in understanding the role of the targetable TRPM2 channel in the context of atherosclerosis, as they report in the March 28, 2022, issue of Nature Cardiovascular Research.

Investigators at the National Institute of Biological Sciences in Beijing and China Agricultural University have identified mixed lineage kinase domain-like protein as an important player in diabetic neuropathy.

In the attempts to improve CAR T-cell function, Neville Sanjana told BioWorld Science, "most of the focus is on making the CAR better."

A multidisciplinary team of scientists has discovered the mechanism that controls synaptic pruning of new neurons in the adult brain. The team discovered that microglial cells control the number of synapses by "eating" excessive synapses.

Researchers at the University of Minnesota have identified a nonhormonal form of contraception for males, which left male mice temporarily sterile after a few weeks of administration.

Researchers at the Albert Einstein College of Medicine have turned pancreatic cancer’s immunosuppressive properties, and mechanisms, against itself. The team have used the bacterium Listeria monocytogenes as a delivery vehicle for tetanus toxoid protein, a highly immunogenic antigen that is used in childhood tetanus vaccinations. In mouse models of pancreatic cancer, treatment reduced both primary tumors and metastases, and extended survival.

Researchers at the University of Queensland have found a genetic link between endometriosis and ovarian cancer subtypes, enabling them to identify potential drug targets for therapy and increasing the understanding of both diseases.

A team of researchers at the National Cheng-Kung University in Taiwan has created monoclonal antibodies (MAbs) that can neutralize the secretory glycoprotein chitinase-3-like-1 (CHI3L1) to stop cancer growth.